Table. Human Papillomavirus (HPV) Responses in 13 Men Who Were HPV16 E6 Seropositive at Baseline From the Study of Prevention of Anal Cancera.
| Patient No./Age, y | Anal | HPV DNA | HPV16 serology | HPV16 MFI (antigen)b | Persistence of seropositivity, mo (antigen) | Follow-up status | |
|---|---|---|---|---|---|---|---|
| Histology | Cytology | ||||||
| ID1/52 | LSIL | LSIL | 45 | E6, E1, E2, E7 | 9446 (E6), 666 (E1), 13810 (E2), 11314 (E7) | NA | OPC (deceased) |
| ID2/47 | HSIL-AIN2c | PHSIL | 56, 59 | E6, E2 | 4461 (E6), 785 (E2) | 24 (E6), 10 (E2) | OPC |
| ID3/45 | NA | Negative | Negative | E6, E7 | 4222 (E6), 2663 (E7) | 47 (E6), 47 (E7) | NA |
| ID4/56 | LSIL | HSIL-AIN3 | 16, 45 | E6 | 7421 (E6) | 38 (E6) | NAd |
| ID5/35 | HSIL-AIN3 | PHSIL | 18, 35, 51, 59 | E6 | 1767 (E6) | 12 (E6) | NA |
| ID6/45 | HSIL-AIN3 | HSIL-AIN3 | 33 | E6 | 1299 (E6) | 34 (E6) | NA |
| ID7/64 | LSIL | LSIL | Negative | E6 | 1664 (E6) | 20 (E6) | NA |
| ID8/56e | HSIL-AIN3 | PINV | 45 | E6 | 1039 (E6) | NA | NA |
| ID9/58 | LSIL | HSIL-AIN3 | 16, 51 | E6 | 824 (E6) | 13 (E6) | NA |
| ID10/49 | HSIL-AIN3 | Unsatisfactory | 16, 31, 51, 68 | E6, E1 | 821 (E6), 443 (E1) | NA | NA |
| ID11/65 | LSIL | PHSIL | 33, 58 | E6 | 2413 (E6) | 24 (E6) | Lost to follow-up |
| ID12/38 | HSIL-AIN3 | Unsatisfactory | 16, 39, 52, 59 | NAf | 811 (E6) | NA | Lost to follow-up |
| ID13/74 | Negative | PLSIL | 16 | NAf | 624 (E6) | NA | Refused follow-up |
Abbreviations: AIN, anal intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; MFI, median fluorescence intensity; NA, not applicable, ie, not persistently seropositive throughout follow-up; OPC, oropharyngeal cancer; PHSIL, possible high-grade squamous intraepithelial lesion; PINV, possible invasion; PLSIL, possible low-grade squamous intraepithelial lesion.
Age (median, 52 years), anal histology, anal cytology, and HPV DNA (types positive) were assessed at baseline; HPV16 serology (antigens positive) assessed at last follow-up visit; HPV16 MFI indicates highest level during follow-up.
Standard MFI cutoffs were applied (ie, HPV16 E6 [484 MFI], E7 [548 MFI], E1 [200 MFI], E2 [679 MFI]).
Immunohistochemistry results positive for p16.
History of throat clearing and recurrent generalized sore throats.
HIV positive.
Seroreverted during follow-up (using the seropositivity cutpoint of 484 MFI units established for anal cancer).